Wegovy and Ozempic contain the exact same active ingredient, semaglutide, made by the same manufacturer. The difference isn’t the drug itself but the dose and what it’s approved to treat. Wegovy tops out at 2.4 mg per week compared to Ozempic’s maximum of 2 mg, and the FDA has approved each one for different purposes. Which is “better” depends entirely on what you’re trying to accomplish.
Same Drug, Different Labels
Both medications are once-weekly injections of semaglutide, a compound that mimics a gut hormone called GLP-1. This hormone slows digestion, reduces appetite, and helps regulate blood sugar. The molecule in your body is identical whether it came from a Wegovy pen or an Ozempic pen.
The critical distinction is regulatory. Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes. Wegovy carries approvals for weight management in adults and adolescents 12 and older with obesity (or overweight with at least one weight-related health condition), for reducing cardiovascular risk in adults with established heart disease and excess weight, and most recently for treating a form of fatty liver disease called MASH with moderate to advanced scarring. These are separate approvals with real consequences for whether your insurance will cover a prescription.
Wegovy Delivers a Higher Dose
The most straightforward advantage Wegovy has for weight loss is dosing. Wegovy’s maintenance dose reaches 2.4 mg weekly, while Ozempic maxes out at 2 mg. That extra 0.4 mg matters. Semaglutide’s weight loss effects are dose-dependent, meaning higher doses produce greater appetite suppression and more weight loss on average. Wegovy is also now available as a daily pill at doses up to 25 mg, giving patients an alternative to injections.
Both medications use a gradual dose escalation to minimize side effects. You start low and increase every four weeks. For Wegovy, the standard path moves through 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose. Ozempic follows a similar ramp-up pattern but stops at a lower ceiling.
Weight Loss Comparison
Clinical trials for both drugs demonstrated significant weight loss, but the trials weren’t designed as head-to-head comparisons, so direct numbers require some caution. Wegovy’s STEP trials, which tested the 2.4 mg dose specifically for weight management, consistently showed average body weight reductions in the range of 15% or more over about 68 weeks in people without diabetes. Ozempic’s SUSTAIN trials focused on blood sugar outcomes in people with type 2 diabetes, with weight loss as a secondary measure, and those patients typically lost less weight, partly because of the lower dose and partly because diabetes itself can make weight loss harder.
If your primary goal is losing weight and you don’t have type 2 diabetes, Wegovy at its higher dose is the more effective option based on available evidence. If you have diabetes and need blood sugar control with some weight loss as a bonus, Ozempic is the purpose-built choice.
Heart and Kidney Benefits
Wegovy has a cardiovascular edge that Ozempic doesn’t carry on its label. The SELECT trial, which studied the 2.4 mg dose in over 17,000 people with heart disease and excess weight, found a 20% reduction in major cardiovascular events like heart attacks, strokes, and cardiovascular death compared to placebo. This led to Wegovy’s FDA approval specifically for cardiovascular risk reduction, an indication Ozempic does not have.
Ozempic, meanwhile, has shown notable kidney benefits. The FLOW trial found that semaglutide at the 1.0 mg dose reduced major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease. Patients on semaglutide also lost kidney function more slowly over time. These results apply specifically to people with diabetic kidney disease, a population where slowing progression can delay or prevent dialysis.
Side Effects Are Essentially the Same
Because the active ingredient is identical, the side effect profiles overlap almost completely. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst during the dose escalation phase and improve as your body adjusts. The higher 2.4 mg dose of Wegovy may cause slightly more GI discomfort than Ozempic’s lower ceiling, though the gradual titration schedule is designed to minimize this.
Both carry the same warnings about rare but serious risks, including inflammation of the pancreas and a potential (seen only in animal studies) thyroid tumor risk. Neither should be used alongside other GLP-1 medications.
Cost and Insurance Coverage
Pricing for both medications has been shifting. For self-pay patients, the Wegovy injectable pen costs about $349 per month, while Ozempic ranges from $349 to $499 monthly depending on the dose. Both offer a discounted $199 price for new patients during the first two months. Wegovy pills through direct-to-consumer channels run between $149 and $299 per month depending on dosage.
Insurance coverage often depends on which condition you’re being treated for. Diabetes medications tend to have broader insurance coverage than weight management drugs, which means Ozempic prescribed for type 2 diabetes is more likely to be covered than Wegovy prescribed for weight loss alone. However, this landscape is changing. Novo Nordisk has announced plans to cut list prices for both drugs by up to 50% for 2027, and expanded Medicare access deals are already in place. Your actual out-of-pocket cost will depend heavily on your specific plan.
Which One Should You Choose
The answer comes down to your medical situation. If you have type 2 diabetes and need blood sugar management, Ozempic is the appropriate, FDA-approved option, and it will likely be easier to get covered by insurance. If your primary goal is weight loss without diabetes, Wegovy’s higher dose and specific weight management approval make it the stronger choice. And if you have established heart disease along with obesity or overweight, Wegovy is the only one of the two with proven cardiovascular risk reduction on its label.
For people who are currently on Ozempic and considering a switch to Wegovy for greater weight loss, the transition is straightforward. Patients on Ozempic 1.0 mg can move to Wegovy at the same 1.0 mg dose, then step up to 1.7 mg for four weeks before reaching the 2.4 mg maintenance dose. The underlying drug never changes, only the amount of it.